A Single-center, Randomized, Double-blind, Placebo-controlled, Intervention Clinical Trial to Evaluate the Efficacy and Safety of "KoreaGinseng F Max" on Blood Circulation Improvement in Adults With Poor Peripheral Blood Flow

Inclusion Criteria: * Men or women aged 20 to under 65 years * Platelet aggregation response above 55% (satisfied for both collagen and ADP) * Provides voluntary written informed consent to participate Exclusion Criteria: * History of hypersensitivity or allergy to ginseng-containing products that may affect the results * Surgery under general anesthesia within 12 weeks before participation * Use of contraindicated products such as red ginseng or omega-3 fatty acids within 2 weeks before screening * Use of antiplatelet drugs such as aspirin within 2 weeks before screening (subjects on prophylactic aspirin \<100 mg with unchanged dose/method may participate) * Uncontrolled hypertension not managed by medication (systolic BP \>160 mmHg or diastolic BP \>97 mmHg) * Currently using study-indicated medications such as those for dyslipidemia or diabetes * On drug treatment with a history of peripheral atherosclerosis and coronary artery disease (peripheral vascular disease, abdominal aortic aneurysm, carotid artery disease) * Coronary artery bypass surgery, vascular anastomosis, pacemaker use, myocardial infarction, heart failure, arrhythmia, or other cardiac disease within 6 months * Infectious inflammatory disease, systemic infection, immune-resistance-related disease, or leukemia (blood cancer) * Irritable bowel syndrome, gastrointestinal resection surgery, or GI-related disease such as Crohn's disease * History of cerebral ischemia or cerebral hemorrhage such as cerebral inf…